SOVREMENNAYA PEDIATRIYA. 2014. 5(61):59-62; doi 10.15574/SP.2014.61.59

Features pharmacotherapy for newborn and premature babies

Ghdanovich O. I., Znamenskaya T. K., Ghdanovich R. I. 
State establishment «Institute of Pediatrics, Obstetrics and Gynecology, National Academy of Medical Sciences of Ukraine», Kyiv

This article describes the features of the physiology of the newborn and premature babies, causing the differences of pharmacokinetics and pharmacodynamics. Describes the main side effects of drug use in this category of patients. 

Key words: newborn, premature, pharmacotherapy, pharmacodynamics, pharmacokinetics

REFERENCES 
1. Жданович ОІ, Коломійченко ТВ. 2013. Основні проблеми сучасної неонатальної фармакотерапії. Современная педиатрия 6: 62-71.

2. Неонатология: национальное руководство. Под ред. академика РАМН Володина НН. 2008. М, ГЭОТАР-Медиа: 749.

3. Нечаев ВН. 2009. Антибиотикотерапия у новорожденных и детей раннего возарста. М, Практическая Медицина: 127.

4. Allegaert K, van den Anker J, Naulers G et al. 2007. Determinants of drug metabolism in early neonatal life. Curr Clin Pharmacol 2(1): 23–29. http://dx.doi.org/10.2174/157488407779422294

5. Allegaert K, van den Anker J, Tayman C, de Hoon J. 2009. Determinants of variability in clearance of exogenous compounds in neonates. Verh K Acad Geneeskd Belg 71(3): 42–64.

6. Allegaert K, Verbesselt R, Naulaers G et al. 2008. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 63: 16–24. http://dx.doi.org/10.1179/acb.2008.003

7. Allegaert K, van de Velde M, van den Anker J. 2014. Neonatal clinical pharmacology. Pediatric Anesthesia 24: 30–38. http://dx.doi.org/10.1111/pan.12176

8. Amin SB, Harte T, Scholer L et al. 2009. Intravenous lipid and bilirubin-albumin binding variables in premature infants. Pediatrics 124(1): 211–217. http://dx.doi.org/10.1542/peds.2008-0846

9. Anderson BJ, Allegaert K. 2010. The pharmacology of anaesthetics in the neonate. Best Pract Res Clin Anaesthesiol 24: 419–431. http://dx.doi.org/10.1016/j.bpa.2010.02.019

10. de Wildt SN. 2011. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 7: 935–948. http://dx.doi.org/10.1517/17425255.2011.577739

11. Johnson TN, Thomson M. 2008. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J Pediatr Gastroenterol Nutr 47(1): 3–10. http://dx.doi.org/10.1097/MPG.0b013e31816a8cca

12. Leeder JS. 2009. Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology. Clin Pharmacol Ther 86: 678-682. http://dx.doi.org/10.1038/clpt.2009.195

13. Lutsar I, Metsvaht T. 2010. Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis. Curr Opin Infect Dis 23(3): 201–217. http://dx.doi.org/10.1097/QCO.0b013e328337bb42

14. McIntyre J, Choonara I. 2004. Drug toxicity in the neonate. Biol Neonate 86(4): 218–221.

15. Meakin G. 2007. Neuromuscular blocking drugs in infants and children. Cont Educ Anaesth Crit Care Pain 7: 143-147.

16. Rodriguez W, Selen A, Avant D et al. 2008. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 121: 530-539.

17. Sistonen J, Madadi P, Ross CJ et al. 2012. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther 91: 692–699. http://dx.doi.org/10.1038/clpt.2011.280

18. Skinner AV. 2012. Neonatal pharmacology. Аnaesthesia and intensive care medicine 3: 79-84.

19. Smits A, Annaert P, Allegaert K. 2011. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Handb Exp Pharmacol 205: 3-49.

20. Smits A, Kulo A, de Hoon JN, Allegaert K. 2013. Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Int J Pharm 452(1-2): 8-13. http://dx.doi.org/10.1016/j.ijpharm.2012.03.035

21. Staelens S, van den Driessche M, Barclay D et al. 2008. Gastric emptying in healthy newborns fed an intact protein formula, a partially and extensively hydrolyzed formula. Clin Nutr 27(2): 264–268. http://dx.doi.org/10.1016/j.clnu.2007.12.009

22. Sumpter A, Anderson BJ. 2009. Pediatric pharmacology in the first year of life. Curr Opin Anaesthesiol 22: 469–475 http://dx.doi.org/10.1097/ACO.0b013e32832bc7ff

23. Tayman C, Rayyan M, Allegaert K. 2011. Neonatal Pharmacology: Extensive Interindividual Variability Despite Limited Size. J Pediatr Pharmacol Ther 16(3): 170–184.

24. Tzialla C, Borghesi A, Perotti GF et al. 2012. Use and misuse of antibiotics in Neonatal Intensive Care Unit. J Matern Fetal Neonatal Med 25: 35–37. http://dx.doi.org/10.3109/14767058.2012.714987

25. Ward RM, Kern SE. 2009. Clinical trials in neonates: a therapeutic imperative. Clin Pharmacol Ther 86: 585-587. http://dx.doi.org/10.1038/clpt.2009.207

26. Zaffanello M, Bassareo PP, Cataldi L et al. 2010. Long-term effects of neonatal drugs on the kidney. J Matern Fetal Neonatal Med 23 (Suppl 3): 87–89. http://dx.doi.org/10.3109/14767058.2010.501156

27. Zhu R, Kiser JJ, Seifart HI et al. 2012. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol 52: 511–519. http://dx.doi.org/10.1177/0091270011402826